Fujifilm Biotechnologies CEO Lars Petersen says CDMOs must expand modalities, embrace AI, and boost biosimilar capacity amid biopharma's $300B patent cliff.
As drugmakers prepare for the looming biopharma patent cliff, 2026 has so far been a year for dealmaking. Now, contract manufacturers need to broaden their …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The tables have turned for the U.S. biosimilars market. | With more than a decade passed since the first FDA biosim approval,…
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of…
Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the…
Amid multiple efforts to rein in steep drug costs in the U.S., Colorado has received the all-clear to take matters into its own…
FDA will end its CMC Development and Readiness Pilot in April 2027 after low participation — only 21 of 27 expected drugmakers…
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue…
